每经记者｜黄小聪 每经编辑｜叶峰 此前，我们已经分多期对比了多个同名ETF以及它们背后跟踪的指数。本期再来对比两组同名ETF：疫苗ETF和卫星ETF。 疫苗ETF 目前有2只产品的名称都是疫苗ETF，其中疫苗ETF（159643.SZ）的管理公司是国泰基金，跟踪的指数是国证疫苗与生物科技指数。 国证疫苗与生物科技指数是由业务涉及生物科技产业的50家证券组成，反映沪深北交易所生物科技产业中优质上市公司的整体表现，成分股的平均市值约 545亿元。 | 元) | | | --- | --- | | 最大値 | 4.231.83 | | 平均值 | 544.57 | | 中位数 | 255.10 | | 最小值 | 79.80 | | 台计 | 27.228.40 | 另一只疫苗ETF（562860.SH）的管理公司是嘉实基金，跟踪的指数是中证疫苗与生物技术指数。 继续对比两个指数目前的估值水平，Wind数据显示，国证疫苗与生物科技指数目前的市盈率TTM处在近十年中位数左右的位置，而中证疫苗与生物技术指 数目前的市盈率TTM回升到历史75%分位以上。 卫星ETF 中证疫苗与生物技术指数是选取不超过50家业务涉及疫苗研 ...

每经记者｜黄小聪 每经编辑｜彭水萍 目前有2只产品的名称都是消费电子ETF，其中消费电子ETF（159732）的管理公司是华夏基金，跟踪的指数是国证消费电子主题指数。 此前，我们已经分多期对比了多个同名ETF以及它们背后跟踪的指数，本期再来对比两个同名ETF：消费电子ETF和科技龙头ETF。 1、消费电子ETF 国证消费电子主题指数是由业务涉及消费电子产业的50家上市公司组成，反映沪深北交易所消费电子产业中优质上市公司的整体表现。个股的平均市值约为 664亿元。 | 最大值 | 4.147.89 | | --- | --- | | 平均值 | 664.13 | | 中位数 | 429.41 | | 最小值 | 149.97 | | 合计 | 33,206.27 | 另一只是消费电子ETF（561600），管理公司是平安基金，跟踪的指数是中证消费电子主题指数。 中证消费电子主题指数选取50只业务涉及元器件生产、整机品牌设计及生产等消费电子相关的上市公司证券作为指数样本。个股的平均市值约为1222亿元。 | 最大值 | 11.968.53 | | --- | --- | | 平均值 | 1.221.97 | | ...

Group 1: Biovaccine ETFs - There are two ETFs named Biovaccine ETF, one managed by Penghua Fund tracking the Guozhen Vaccine and Biotechnology Index, consisting of 50 companies with an average market capitalization of approximately 53.9 billion yuan [1][3] - The second Biovaccine ETF is managed by Harvest Fund, tracking the Zhongzheng Vaccine and Biotechnology Index, which includes up to 50 companies involved in vaccine research and production, with an average market capitalization of about 22 billion yuan [3][5] - The two indices share 19 overlapping constituent stocks, with the Guozhen index having 31 unique stocks and the Zhongzheng index having 24 unique stocks [5][6] - In terms of past performance, the Zhongzheng Vaccine and Biotechnology Index has outperformed the Guozhen index over one, three, and five years, with a notably higher increase in the past year [6][7] Group 2: Biopharmaceutical ETFs - There are two ETFs named Biopharmaceutical ETF, one managed by Tianhong Fund tracking the Guozhen Biopharmaceutical Index, which includes the top 30 companies based on market capitalization and liquidity, with an average market capitalization of around 45.2 billion yuan [11][13] - The second Biopharmaceutical ETF is managed by Guotai Fund, tracking the Zhongzheng Biopharmaceutical Index, which selects companies providing cell therapy, gene sequencing, and other biopharmaceutical services, with an average market capitalization of approximately 71.9 billion yuan [13][15] - The two indices have 18 overlapping constituent stocks, with each index having 12 unique stocks [15][16] - The Zhongzheng Biopharmaceutical Index has consistently outperformed the Guozhen index over one, three, and five years, while the Guozhen index exhibits higher annualized volatility [15][17]